Insights
Not AI news. Not vendor hype. Practical perspectives from working inside complex, compliance-driven workflows every day.
The FDA's 2026 AI framework isn't a future concern — the PCCP guidance is already in effect for new submissions. Here's what that actually means for mid-market device manufacturers trying to ship AI-enabled products.
Stanford's new AI Playbook analyzed 51 real deployments. The top reasons they failed have nothing to do with the model — and everything to do with how your organization actually works.
Most distributors aren't losing margin because their forecasting model is bad. They're losing it because their bad forecast sits uncorrected for too long. That's a workflow problem, not a software problem.
Task-level AI wins are real. But if you're not seeing it in your operations, the problem isn't the AI — it's where you plugged it in.
Big banks going to production with AI tells you something important — but not what the headlines say. For mid-market financial services firms, the real question isn't whether AI works. It's whether your org can actually run it.
Every AI automation vendor claims production-ready. Most mean 'it worked in the demo.' Here's how to evaluate vendors the way a regulated industry actually needs to.
The bottleneck in most mid-market AI deployments isn't the model. It's the infrastructure underneath it — and the compliance overhead baked into every layer.
Everyone's excited about agentic AI in manufacturing. Almost no one has the data infrastructure to actually run it. Here's what mid-market operators need to understand before they commit.
The research is in: only 5% of enterprises see substantial AI returns. For mid-market operators in regulated industries, that number should be a wake-up call — not about AI itself, but about how you're deploying it.
Most regulated companies celebrate a successful AI pilot. They shouldn't. The pilot is where AI goes to die quietly — and the medical device industry is proof.
Every regulated industry is shopping for AI governance platforms in 2026. Most are buying tools before they've answered the harder question: who actually owns AI risk inside your organization?
Most AI adoption research treats "struggling" as a fixable technology problem. In regulated industries, it's a workflow design problem — and the fix looks completely different.
NVIDIA's 2026 State of AI report says companies are seeing real revenue gains and cost cuts from AI. Mid-market operators in regulated industries are largely watching from the sidelines. Here's why — and what to do about it.
Everyone is talking about AI on the manufacturing floor. Almost nobody is talking about what happens six months after go-live when the change control queue is full and the shift supervisor still doesn't trust the system.
Most manufacturers have a proof-of-concept that impressed someone in a conference room. Very few have AI that runs in production without a babysitter. Here's why — and what to do about it.
Enterprise AI automation platforms look impressive in demos. But most mid-market manufacturers don't have the infrastructure, the IT staff, or the change control process to survive implementation. Here's what to do instead.
Every mid-market operator knows AI matters. Almost none of them have figured out where to actually put it to work. Here's why the 'where to start' question is a distraction — and what to ask instead.
Boards and executives are being told to institutionalize AI governance as a core competency. For mid-market companies in regulated industries, that mandate is arriving before most of them have a working governance structure to build from.
Nearly every manufacturer is looking at AI. Almost none of them have the data infrastructure to run it. That's not an AI problem — it's an operations problem.
Every year a new ranked list of automation platforms drops, and every year mid-market operators in regulated industries buy the wrong thing for the wrong reasons. Here's what the rankings don't tell you.
Most mid-market companies in regulated industries have an AI policy now. Almost none of them have figured out how to actually run it. That gap is where the real compliance risk lives.
Regulated industries keep buying better AI models and still failing compliance reviews. The problem isn't the model — it's everything the model touches.
Everyone is adding AI tools to their workflow. Almost nobody is connecting them to a process that survives compliance review. Here's what that gap actually costs you.
The workflow automation market is booming. But the platforms driving that growth were designed for GTM teams at SaaS companies — not for ops managers at medical device firms trying to keep compliance teams happy.
Most financial services firms bolt compliance onto AI workflows as an afterthought. That's exactly why their implementations fail — and why the firms getting traction are building the opposite way.
Every retail and CPG company is chasing AI-driven demand forecasting and supply chain orchestration. Almost none of them are asking the right question first: who actually owns the decision the AI is informing?
Everyone's chasing AI transformation. The companies actually seeing returns are targeting something much smaller — the dead time between steps. Here's what that looks like in practice.
FDA's evolving AI/ML SaMD framework isn't a checklist you complete at launch. It's a continuous obligation — and most mid-market device companies aren't built for that.
Every 2026 survey shows retail and CPG leaders bullish on AI. The production reality is far messier — and mid-market operators are the ones absorbing the gap.
The FDA is being pushed to apply clinical laboratory validation standards to AI in medical devices. If you're building AI workflows in this space, that changes the math on what 'ready to deploy' actually means.
MIT research says 95% of enterprise AI projects don't deliver ROI. In regulated industries, the number feels even higher — and the reason isn't the technology.
Every workflow automation vendor is pitching AI-powered efficiency in 2026. Here's why picking the platform before solving the governance problem is how regulated-industry companies end up with a very expensive mess.
Everyone's talking about the 95% failure rate for enterprise AI. But for mid-market operators in regulated industries, the failure mode looks very different — and so does the fix.
Mid-market manufacturers keep buying enterprise AI tools and watching them stall at the integration layer. The problem isn't the algorithm — it's everything the algorithm has to talk to.
The medical device companies getting buried by FDA's evolving AI framework aren't failing on regulatory knowledge — they're failing because they bolted compliance onto a workflow that was never built to carry it.
Everyone in financial services is talking about converging their AI into one unified architecture. Most of them are about to make the same expensive mistake.
Most medical device companies are treating FDA's new AI requirements as a regulatory checkbox. That's exactly why they'll fail. Here's what the framework actually demands — and what it means for how you build.
Manufacturers are pouring money into AI pilots while their scheduling runs on spreadsheets and tribal knowledge. The use cases with the fastest payback aren't the flashy ones.
Everyone's automating invoice coding. Almost nobody is building the compliance scaffolding that makes it stick. Here's the gap mid-market CFOs keep falling into.
Everyone's talking about AI-driven inventory automation. Most mid-market operators are still running on spreadsheets and gut feel. Here's the gap — and how to close it without blowing up your ops.
The FDA's finalizing AI guidance that demands explainability, transparency, and real-world monitoring — and most mid-market device makers aren't remotely ready. Here's what that actually means for your workflows.
MIT found that 95% of enterprise AI pilots deliver zero measurable ROI. For companies in medical device, financial services, or manufacturing, the failure rate isn't just a budget problem — it's a compliance and operational risk.
Manufacturers are moving AI out of the pilot lab and into operations. That's the good news. The hard part — integration, compliance, and change control — is just getting started.
Mid-market manufacturers keep buying AI tools and getting marginal results. The problem isn't the tools — it's that nobody connected them to anything that matters.
Most financial services firms are building AI governance programs that look good on paper and collapse under operational weight. Here's what actually works.
FDA easing oversight on lower-risk AI devices sounds like good news. For mid-market manufacturers, it's actually a trap if you haven't built the right internal scaffolding first.
FDA and EU regulators are locking in AI oversight frameworks for 2026. Most mid-market medical device companies aren't close to ready — and the gap isn't technical, it's operational.
The FDA's 2025 draft guidance on AI-enabled devices buried a major compliance shift inside a document that doesn't even say 'human factors' in the title. Here's what it actually means for your validation strategy.
The FDA just drew clearer lines around AI in medical devices. For mid-market operators, this isn't a compliance headache — it's a forcing function that separates serious AI programs from expensive experiments.
New posts go out when they're ready — no filler, no cadence for cadence's sake.
Get in Touch